TY  - JOUR
AU  - Van Cutsem, E
AU  - Yoshino, T
AU  - Lenz, H J
AU  - Lonardi, S
AU  - Falcone, A
AU  - Limón, M L
AU  - Saunders, M
AU  - Sobrero, A
AU  - Park, Y S
AU  - Ferreiro, R
AU  - Hong, Y S
AU  - Tomasek, J
AU  - Taniguchi, H
AU  - Ciardiello, F
AU  - Stoehr, J
AU  - Oum'Hamed, Z
AU  - Vlassak, S
AU  - Studeny, M
AU  - Argiles, G
PY  - 2018
DO  - 10.1093/annonc/mdy241
UR  - http://hdl.handle.net/10668/12712
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - Angiogenesis is critical to colorectal cancer (CRC) growth and metastasis. Phase I/II studies have demonstrated the efficacy of nintedanib, a triple angiokinase inhibitor, in patients with metastatic CRC. This global, randomized, phase III study...
LA  - en
KW  - Adenocarcinoma
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents
KW  - Chemical and Drug Induced Liver Injury
KW  - Colorectal Neoplasms
KW  - Disease Progression
KW  - Double-Blind Method
KW  - Fatigue
KW  - Female
KW  - Humans
KW  - Indoles
KW  - Male
KW  - Middle Aged
KW  - Placebos
KW  - Progression-Free Survival
KW  - Protein Kinase Inhibitors
KW  - Receptors, Vascular Endothelial Growth Factor
KW  - Response Evaluation Criteria in Solid Tumors
TI  - Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study.
TY  - research article
VL  - 29
ER  -